Grape Seed Extract Shows Potential to Slow Prostate Cancer Progression
/in Clinical Trial, Non-Metastatic, Phase 2/by MaxBA1106 Antibody Shows Promise in Early Trials In Solid Tumors
/in Clinical Trial, Not PCa related/by MaxQ702 Drug Shows Promise in Early Trials: Could Be Useful Against Prostate Cancer
/in Clinical Trial, Not PCa related/by MaxNezastomig (REGN5678): New Drug Combo Shows Promise In mCRPC, But Safety Is A Concern
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxA New Potential Treatment For Early Prostate Cancer: TGW101
/in Clinical Trial, Non-Metastatic, Not PCa related, Phase 1/by MaxNext-Generation ADCs for Cancer Treatment with Potential in Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase1/2: Kesonotide For Metastatic Castration-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1 Trial: GEN1057 Bispecific-Antibody In Metastatic Solid Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 37/2026 September 13, 2026
- Reading the DNA Fingerprints of Prostate Cancer September 12, 2026
- Phase 1/2 Trial Results for Tinengotinib (TT-00420) in mCRPC September 12, 2026
- STAMINA: Supervised Exercise and Dietary Advice Cut ADT-Related Decline in Prostate Cancer September 8, 2026